The quarter missed the only meaningful published financial benchmark. EPS came in at a $0.53 loss versus a published consensus of roughly a $0.47 loss, a $0.06 miss; there is no revenue comparison because Edgewise remains pre-commercial.
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Net loss | $57.3 million | $36.1 million in Q2 2025 (Income Statement) |
| Loss per share | $0.53 | $0.34 loss in Q2 2025; approximately $0.47 expected |
| R&D expense | $47.5 million | $33.6 million in Q2 2025 (Income Statement) |
| G&A expense | $14.4 million | $9.1 million in Q2 2025 (Income Statement) |
| Cash, equivalents and marketable securities | $460.7 million | $530.1 million at December 31, 2025 (Balance Sheet) |
| Pro forma cash after upfront proceeds | $2.01 billion | Includes $1.55 billion received from Servier; before taxes and transaction costs (Cash, cash equivalents and marketable securities) |
The balance-sheet transformation is the bigger event, but it was largely known already. The previously announced Servier transaction closed in July, transferring sevasemten and the muscular dystrophy business for $1.55 billion upfront and up to $1.1 billion in milestones; the filing mainly confirms completion and shows the resulting pro forma cash position (Transaction highlights; Cash, cash equivalents and marketable securities).
The company now has unusually strong funding for a narrower, cardiovascular-focused pipeline. Management reiterated plans to start an EDG-7500 Phase 3 HCM trial in the fourth quarter of 2026 and an EDG-15400 HFpEF Phase 2 trial in the second half of 2026, while quarterly R&D rose 42% year over year to support those programs (CIRRUS-HCM Phase 2; EDG-15400 and heart failure; R&D expenses). That improves financial flexibility, but the filing adds no new efficacy data beyond the previously announced positive top-line CIRRUS-HCM results.
Net read: a financial miss offset by a strategically important but already anticipated funding event. The EPS shortfall and rising operating costs are mildly unfavorable, while the $2.01 billion pro forma cash balance materially reduces near-term financing risk; with no new clinical upgrade or surprise milestone, the overall message is mixed rather than clearly positive.
Read the original 8-K on SEC EDGAR ↗